Radiolabeled peptide probe for tumor imaging  

作　　者：Ya-Qiong Yan Hao Wang Yuliang Zhao 

机构地区：[1]CAS Center for Excellence in Nanoscience,CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety,National Center for Nanoscience and Technology(NCNST),Beijing 100190,China

出　　处：《Chinese Chemical Letters》2022年第7期3361-3370,共10页中国化学快报（英文版）

基　　金：supported by the National Key R&D Program of China(No.2018YFE0205400)。

摘　　要：Radionuclide imaging is now the premier imaging method in clinical practice for its high sensitivity and tomographic capability.Current clinically available radio imaging methods mostly use positron-emission tomography(PET)and single-photon emission computed tomography(SPECT)to detect anatomic abnormalities that conventional imaging techniques typically have challenges for visualizing.Contrast agents are indispensable for radionuclide imaging,and the radionuclide is always attached to a suitable vector that achieves targeted delivery.Nowadays,peptides have attracted increasing interest in targeting vectors of contrast agents,mainly due to their high specificity for target receptors at nanomolar concentrations and low toxicity.Radiolabeled peptide probes as kinds of PET/SPECT tracers had become essential tools for clinical radionuclide diagnosis.This review mainly summarizes radiolabeled peptide probes for bioimaging,including fundamental concepts of radiolabeled peptide probe design,some typical peptide analogs radiocontrast agents for PET,SPECT,and the combination imaging.

关 键 词：PEPTIDE Positron-emission tomography(PET) Single-photon emission computed tomography(SPECT) BIOIMAGING 

分 类 号：R730[医药卫生—肿瘤] O657.3[医药卫生—临床医学]